New drug BW-41012 enters first human safety tests

NCT ID NCT07584876

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial will test the safety and tolerability of a single injection of BW-41012 in 40 healthy adults aged 18 to 65. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug behaves in the body. The study does not aim to treat any disease, but to gather essential safety data before moving to patient trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BW-41012 (injection)

What could go wrong

This is a very early, small study in healthy people, not patients. It only checks safety and how the drug moves in the body, not whether it works for any disease. Many early-stage drugs fail to show benefit later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hydroa vacciniforme

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Argo Investigative Site

    Perth, Western Australia, Australia